findmyKOL

Shaker Dakhil, MD

Basic profile

Cancer Center of Kansas

ORCIDNPI
RegionWichita, KS · MidwestSpecialtyHematology / OncologyFocusOncology
Last active 2018findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2001–2018Why? →

Shaker Dakhil is an Oncology physician affiliated with Cancer Center of Kansas. OpenAlex indexes 452 publications with 38,028 citations (h-index 81). By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
452publications

Distinct works indexed by OpenAlex, matched via ORCID.

38,028citations

Total citations across indexed works.

81h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
25companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2001–2018

Federally funded research awards.

View funding

Industry payments

25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

25 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    39.9%
    PD-1 inhibitor18.8%
    Pembrolizumab55%Nivolumab45%
    Part B, office-administered40 patients
    Platinum-based Drug6.3%
    Oxaliplatin97%Carboplatin3%
    Part B, office-administered43 patients

    + 15 more classes in this area

  • Blood & clotting

    28.1%
    Iron, parenteral preparations20.8%
    Ferric carboxymaltose100%
    Part B, office-administered41 patients
    Erythropoiesis-stimulating Agent7.3%
    Darbepoetin alfa58%Epoetin alfa42%
    Part B, office-administered26 patients
  • Metabolism & gastrointestinal

    17.1%
    Substance P/Neurokinin-1 Receptor Antagonist9.5%
    Aprepitant100%
    Part B, office-administered103 patients
    Serotonin-3 Receptor Antagonist7.1%
    Granisetron82%Ondansetron hydrochloride14%Palonosetron hcl4%Ondansetron Hcl0%Ondansetron Odt0%
    Part D + Part B84 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 20012018 per NIH RePORTER. The latest:

19 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”